(UroToday.com) The American Urologic Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Behfar Ehdaie discussing results of a phase IIb multicenter study assessing MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer. Radical whole-gland therapy for prostate cancer can lead to significant side effects, including a decline in erectile function and urinary continence. Patients with Grade Group 2 or 3 prostate cancer are often ineligible for active surveillance or experience early disease progression (40% within 5 years in ProtecT1) on active surveillance requiring radical therapy. Focal therapy has emerged as an alternative treatment with the goal to reduce side effects and maintain cancer control by targeting areas of known cancer with the prostate gland. Multicenter, retrospective studies have shown focal therapy for prostate cancer is safe and reported approximately 80% of men require no further prostate-cancer-directed treatment.2 This study investigated whether targeted focal therapy using ExAblate MRI-guided focused ultrasound can safely treat Gleason Grade Group 2/3 prostate cancer patients in a single-arm, multicenter phase IIb clinical trial.